Department of Otolaryngology, Elsan Hospital, Paris, France.
Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Avenue du Champ de mars, 6, B7000, Mons, Belgium.
Eur Arch Otorhinolaryngol. 2022 Sep;279(9):4629-4632. doi: 10.1007/s00405-022-07426-3. Epub 2022 May 11.
To investigate the mid-to-long-term symptom evolution and treatment findings of laryngopharyngeal reflux (LPR) patients.
Patients with LPR and treated between September 2016 and December 2017 were prospectively followed. The diagnosis consisted of > 1 pharyngeal event at the hypopharyngeal-esophageal multichannel intraluminal impedance-pH monitoring. The treatment consisted of 3- to 9-months diet, stress management and medication according to the type of LPR. Reflux symptom score was used to assess the therapeutic response. Patients were surveyed yearly to know the reflux evolution, the potential recurrence(s) of symptoms, and the approaches used to control the disease.
A total of 77 patients completed the evaluations (45 females). The initial treatment duration was 3, 6, or 9 months in 25 (32.5%), 23 (29.9%), and 6 (7.7%) cases before weaning, respectively. Twenty-three patients (29.9%) reported chronic course of the disease. According to the reduction of reflux symptom score, symptoms did not change in 11 (14.3%) patients, while the rest of the patients reported symptom reduction or relief (responder rate of 85.7%). Over time, LPR symptoms never relapsed in 31% of cases, while 38% of patients reported one or several recurrences a year. The recurrence episodes of patients were all adequately treated with medication or diet and did not require long-term medication.
Chronic course of the disease was observed in 31% of patients who required long-term medication. Preliminary observations reported that LPR may be classified as acute, recurrent, or chronic disease. The medication weaning is possible in most patients, leading to reduction of cost burden related to LPR treatment.
研究咽喉反流(LPR)患者的中-长期症状演变和治疗结果。
前瞻性随访 2016 年 9 月至 2017 年 12 月间接受治疗的 LPR 患者。诊断标准为:咽食管多通道腔内阻抗-pH 监测显示>1 次咽部反流事件。治疗包括根据 LPR 类型进行 3-9 个月的饮食、压力管理和药物治疗。反流症状评分用于评估治疗反应。每年对患者进行调查以了解反流演变、症状潜在复发情况以及控制疾病的方法。
共 77 例患者完成评估(45 例女性)。初始治疗持续时间分别为 3、6 或 9 个月,分别为 25 例(32.5%)、23 例(29.9%)和 6 例(7.7%)患者在停药前的治疗时间。23 例(29.9%)患者报告疾病呈慢性病程。根据反流症状评分的降低,11 例(14.3%)患者的症状无变化,其余患者报告症状减轻或缓解(缓解率为 85.7%)。随着时间的推移,31%的患者 LPR 症状从未复发,而 38%的患者每年报告 1 次或多次复发。患者的复发发作均通过药物或饮食治疗得到有效治疗,无需长期药物治疗。
31%的患者需要长期药物治疗,观察到疾病呈慢性病程。初步观察报告表明,LPR 可能被分为急性、复发性或慢性疾病。大多数患者可以逐渐减少药物治疗,从而减轻与 LPR 治疗相关的费用负担。